| US 7,541,375 B2 | ||
| Azole derivatives and pharmaceutical compositions containing them | ||
| Stephen J. Arkinstall, Belmont, Mass. (US); Antonio Arulanandam, Winchester, Mass. (US); Xuliang Jiang, Braintree, Mass. (US); Sharad Magar, Canton, Mass. (US); Roustem Nabioullin, South Burlington, Vt. (US); John Yingsheng Zhang, Foxboro, Mass. (US); and Peter Blume-Jensen, Newton, Mass. (US) | ||
| Assigned to Laboratoires Serono SA, Coinsins (Switzerland) | ||
| Filed on Jul. 24, 2007, as Appl. No. 11/782,251. | ||
| Application 11/782251 is a division of application No. 10/491902, granted, now 7,253,199, previously published as PCT/US02/33963, filed on Oct. 23, 2002. | ||
| Claims priority of provisional application 60/336040, filed on Oct. 23, 2001. | ||
| Prior Publication US 2007/0293555 A1, Dec. 20, 2007 | ||
| Int. Cl. A61K 31/415 (2006.01); C07D 233/00 (2006.01) | ||
| U.S. Cl. 514—385 [548/300.1; 548/311.1] | 26 Claims |
1. A method for treating a mammal suffering from or susceptible to a cancer selected from the group consisting of breast cancer,
ovarian cancer, and colon cancer, comprising administering to the mammal in need of said treating an effective of amount of
a compound of the following Formula I:
 wherein each of A1, A2, and A4 are carbon and A3 is nitrogen;
each R is independently halo, nitro, optionally substituted alkyl; optionally substituted alkenyl; optionally substituted
alkynyl; optionally substituted heteroalkyl; optionally substituted heteroalkenyl; optionally substituted heteroalkynyl; optionally
substituted alkanol; optionally substituted aryl, optionally substituted heteroalicyclic, optionally substituted heteroaromatic,
optionally substituted aralkyl; optionally substituted heteroarylalkyl; and optionally substituted heteroalicyclicalkyl;
or two R groups on adjacent ring atoms are taken together with the ring atoms to which they are bonded to form a fused alicyclic,
heteroalicylic, aryl or heteraromatic group having from 4 to about 8 ring members;
k is an integer;
Y is selected from the group consisting of CH2CH, CH2CH(CH2)q, CH2CR7CH2, and a branched alkyl having the formula CH2CH(CH2)p(CH2)s, wherein R7 is H or C1-C6 alkyl, s and p are the same or different and are zero or a positive integer, and q is a positive integer;
W and W′ are each independently a heteroatom; optionally substituted heteroalkyl; optionally substituted heteroalkenyl; and
optionally substituted heteroalkynyl;
Z and Z′ are each independently a chemical bond or alkanoyl; R1 and R2 are each independently optionally substituted aryl or optionally substituted heteroaromatic; and a pharmaceutically acceptable
salt or enantiomer thereof, with the caveat that the compound of Formula I is not a racemate of 4-methoxy benzoic acid 1-imidazol-1-yl
methyl-2-phenoxy ethyl ester, 4-chloro benzoic acid 1-imidazol-1-yl methyl-2-phenoxy-ethyl ester, or benzoic acid 1-imidazol-1-yl
methyl-2-phenoxy-ethyl ester.
|